Table 1.
Patients’ baseline characteristics.
| Characteristics | Control group (n=21) | Telephone care group (n=21) | TECCUa care group (n=21) | |
| Age (years), median (range) | 39.31 (22-61) | 40.91 (24-60) | 41.32 (19-66) | |
| Sex, n (%) | ||||
|
|
Male | 12 (57) | 12 (57) | 9 (43) |
|
|
Female | 9 (43) | 9 (43) | 12 (57) |
| Education, n (%) | ||||
|
|
Primary | 4 (19) | 4 (19) | 5 (23) |
|
|
Secondary | 9 (43) | 6 (29) | 6 (29) |
|
|
University | 8 (38) | 11 (52) | 10 (48) |
| Disease profile, n (%) | ||||
|
|
Crohn disease | 14 (67) | 13 (62) | 13 (62) |
|
|
Ulcerative colitis | 7 (33) | 8 (38) | 8 (38) |
| Median time since diagnosis, months (range) | 123.32 (6-427) | 108.27 (7-452) | 146.72 (7-424) | |
| Treatment, n (%) | ||||
|
|
Immunomodulators | 10 (48) | 10 (48) | 9 (43) |
|
|
Biologic monotherapy | 4 (19) | 4 (19) | 4 (19) |
|
|
Combination therapy | 6 (29) | 5 (24) | 6 (29) |
|
|
Corticosteroids | 1 (5) | 2 (10) | 2 (10) |
| Calprotectin (μg/g), median (IQRb) | 330 (103-617) | 526 (115-1724) | 490 (23-2016) | |
| Quality-of-life scores, median (IQR) | ||||
|
|
IBDQ-9c | 38.50 (33.25-46.75) | 37.50 (28.75-46.25) | 42.00 (33.75-47.50) |
|
|
EQ-5Dd | 0.82 (0.75-0.91) | 0.83 (0.71-0.92) | 0.83 (0.58-0.91) |
|
|
Visual analog scale (%) | 60.50 (50-85) | 62.50 (50-80) | 60 (40-90) |
| Medication adherence, n (%) | 14 (67) | 7 (33) | 12 (57) | |
| Work Productivity and Activity Impairment questionnaire responses | ||||
|
|
Not working, n (%) | 8 (38) | 7 (33) | 5 (24) |
|
|
Work hours missed, % median (IQR) | 27.50 (0-52) | 40 (15-62.50) | 32.50 (7.50-57.50) |
|
|
Work impairment score, median (IQR) | 7 (2.75-10) | 7 (3-10) | 10 (2.25-10) |
|
|
Social impairment score, median (IQR) | 3.50 (1-5.75) | 3.50 (2-7) | 6 (2.75-8) |
| Satisfaction score, median (IQR) | 49.50 (42.50-53.75) | 53 (50-59) | 52 (47.50-55) | |
aTECCU: Telemonitoring of Crohn’s Disease and Ulcerative Colitis.
bIQR: interquartile range.
cIBDQ-9: Inflammatory Bowel Disease Questionnaire 9.
dEQ-5D: EuroQol 5 dimensions questionnaire.